证券代码：603658 证券简称：安图生物 公告编号：2025-082 郑州安图生物工程股份有限公司 （二）现金管理金额 不超过1.4亿元公开发行可转换公司债券闲置募集资金和不超过15.4亿元非 公开发行股票闲置募集资金。 （三）资金来源 1.公司公开发行可转换公司债券闲置募集资金: 关于使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、现金管理情况概述 （一）现金管理目的 本次现金管理是在确保不影响募投项目正常实施、保证募集资金安全的前提 下使用部分暂时闲置募集资金进行的，可以更好地实现公司募集资金的保值增值， 增加公司收益，维护公司全体股东的利益。 投资种类：结构性存款、大额存单、国债逆回购、券商收益凭证、券 商理财产品等安全性高、流动性好的保本型产品，产品期限或剩余期 限不得超过 12 个月 投资金额：不超过 1.4 亿元公开发行可转换公司债券闲置募集资金和 不超过 15.4 亿元非公开发行股票闲置募集资金 已履行及拟履行的审议程序：郑州安图生物工程股份有限公司（以下 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-081 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 郑州安图生物工程股份有限公司 第五届董事会第九次会议决议公告 郑州安图生物工程股份有限公司（以下简称"安图生物"或"公司"）第五 届董事会第九次会议的会议通知和材料于2025年12月6日以电子邮件方式发出，会 议于2025年12月9日在公司会议室以现场和通讯相结合的方式召开，会议应参加董 事12名，实际参加表决董事12名（其中董事张亚循先生、独立董事袁华刚先生以 通讯方式参会，董事杨增利先生以委托方式参会）。会议由公司董事长苗拥军先 生主持，公司部分高级管理人员列席了本次会议。 会议的召集和召开程序符合《公司法》等有关法律、行政法规、部门规章、 规范性文件和《公司章程》的相关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，以记名投票表决方式一致通过以下议案： 1. 审议通过《关于使用闲置募集资金进行现金管理的议案》 内容详见公司同日在上海证 ...

Core Viewpoint - Antu Biology announced the approval of a proposal to utilize idle raised funds for cash management to enhance fund efficiency [1] Group 1: Fund Management - The company plans to use up to 140 million yuan of idle funds from convertible bonds and up to 1.54 billion yuan from non-publicly issued stock for investments in safe and liquid principal-protected products [1] - The investment options include structured deposits, large certificates of deposit, reverse repos of government bonds, broker income certificates, and broker wealth management products [1] - The approved cash management plan is valid for 12 months from the date of the board's approval, allowing for rolling use of funds within the specified limits [1] Group 2: Impact on Operations - The company clarified that this cash management initiative will not affect the progress of investment projects funded by the raised capital or the normal production and operation of the company [1]

Summary of Conference Call Records Industry Overview - The medical device industry is experiencing overall performance pressure in 2025, but third-quarter revenues have shown a year-on-year increase, with a narrowing decline in net profit attributable to the parent company, primarily due to domestic medical insurance cost control and geopolitical influences. It is expected that normal growth rates will resume in 2026 [1][3][8]. Key Points on Medical Device Sector - **Domestic Market Dynamics**: The slowdown in hospital bidding in 2024 is impacting revenue realization, with an expected boost from the "old-for-new" policy by the end of 2025. The In Vitro Diagnostics (IVD) sector is under pressure due to centralized procurement price adjustments and tax reimbursements [1][4]. - **International Market Challenges**: Companies are strengthening their overseas presence, but initial high costs are pressuring short-term profits. The impact of US-China tariffs on low-value consumables is significant, with expectations of price recovery in the glove industry from late 2025 to 2026 after inventory digestion [1][4][11]. - **Performance Metrics**: In the first three quarters of 2025, the medical device sector reported revenues of 145.7 billion yuan, a year-on-year decline of 2.4%, and a net profit of 26.5 billion yuan, down 14.4%. However, the third quarter showed a positive revenue trend and a narrowing profit decline [3][15]. Specific Sector Insights - **IVD Sector**: The IVD sector saw a year-on-year decline of 14.5% in the first three quarters, but the third quarter showed improvement with revenues of 11.02 billion yuan, benefiting from the implementation of centralized procurement and the release of DRG/DIP 2.0 [16]. - **High-Value Consumables**: This segment experienced a revenue growth of 6.6% year-on-year, with orthopedics showing a significant growth rate of 18.7%. The recovery in cardiovascular surgeries is driving sales, and the ophthalmology sector presents potential due to low penetration rates [17]. - **Medical Equipment**: The medical equipment sector's revenue remained flat, but profit growth was slightly higher. The imaging equipment sector is benefiting from the "old-for-new" projects, with a notable recovery in the endoscope segment [15]. Vaccine Sector Performance - The vaccine sector faced significant pressure, with revenues declining nearly 50% and profits turning negative. However, there is a quarter-on-quarter improvement trend. Future focus includes the recovery of traditional vaccines and the launch of new pipeline products, such as the domestically produced nine-valent HPV vaccine [2][23]. Life Sciences Upstream Sector - The life sciences upstream sector's performance remained stable, with a year-on-year profit growth of 68% in the third quarter, driven by recovering terminal demand and improved gross margins. The sector is benefiting from the expansion of the biopharmaceutical market and policy support [24]. Regulatory Environment and Challenges - The current regulatory environment emphasizes innovation while ensuring safety and efficacy. Domestic companies face challenges in international certifications, particularly with the FDA and CE, due to quality control issues [20][21][22]. Future Outlook - The industry outlook for 2026 includes a focus on self-sufficiency, innovative devices, and accelerated realization of centralized procurement categories. The recovery of orthopedic products is already evident, and international expansion remains a key area of interest [5][7][19].

Core Viewpoint - Antu Biology (603658.SH) has received medical device registration certificates from the National Medical Products Administration and the Henan Provincial Medical Products Administration, enhancing its product offerings and competitiveness in the market [1] Group 1: Company Developments - The company and its wholly-owned subsidiary, Zhengzhou Sikun Biological Engineering Co., Ltd., along with its secondary subsidiary, Zhengzhou Biaoyuan Biotechnology Co., Ltd., have recently obtained medical device registration certificates [1] - The acquisition of these certificates enriches the company's product menu and meets market demand, serving as an effective supplement to existing testing products [1] Group 2: Market Impact - The new medical device registration is expected to gradually improve the overall competitiveness of the company's products [1] - The short-term impact on the company's operating performance is considered to be minimal [1]

智通财经APP讯，安图生物(603658.SH)发布公告，公司及全资子公司郑州思昆生物工程有限公司(简 称"思昆生物")、二级子公司郑州标源生物科技有限公司(简称"郑州标源")分别于近日收到国家药品监督 管理局、河南省药品监督管理局颁发的医疗器械注册证。 上述医疗器械注册证的取得进一步丰富了公司产品菜单，不断满足市场需求，是对公司现有检测产品的 有效补充，可以逐步提高公司产品的整体竞争力，短期内对公司的经营业绩影响较小。 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-080 郑州安图生物工程股份有限公司 关于公司及子公司获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）及全 资子公司郑州思昆生物工程有限公司（以下简称"思昆生物"）、二级子公司郑 州标源生物科技有限公司（以下简称"郑州标源"）分别于近日收到国家药品监 督管理局、河南省药品监督管理局颁发的医疗器械注册证，具体如下： | 编号 | 产品名称 | 注册证编号 | 注册证 | 预期用途 | 所属 | | --- | --- | --- | --- | --- | --- | | | | | 有效期 | | 公司 | | | 基因测序仪（型号： | 国械注准 | | 该产品采用可逆末端终止测序法，用 于对来源于人体样本中人的脱氧核 | 思昆 生物 | | | | | | 糖核酸（DNA）进行测序，以检测 | | | | | | | 基因序列，这些基因序列可用于辅助 | | | 1 | S ...

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [6][54]. Core Viewpoints - The IVD market is expected to benefit from a recent policy initiative aimed at enhancing the adaptability of supply and demand for consumer goods, with a focus on high-end medical devices and efficient IVD equipment [5][53]. - The domestic biochemical diagnostics sector has largely overcome reliance on foreign technologies, indicating a completed process of localization [6][54]. - The report emphasizes the shift towards home health management, moving from a treatment-centered to a prevention-centered approach, which is expected to create a trillion-yuan integrated market [5][53]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 2.67%, with the IVD sector increasing by 2.63% during the week [2][12]. - The IVD sector's current PE ratio is 39.84X, with a PB ratio of 1.85X, reflecting a slight increase from the previous week [4][33]. Company Performance - Notable performers in the medical services sector include Haobio (+14.3%), Shuoshi Biological (+13.6%), and Innotech (+13.3%) [3][29]. - Underperformers include *ST Dongyang (-7.2%) and New Industry (-5.7%) [3][29]. Investment Recommendations - The report suggests focusing on companies in the IVD sector that cater to home consumption scenarios, such as Shengxiang Biological and Sannuo Biological [5][54]. - It highlights the importance of monitoring the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics like PCR [6][54].

投资者可于 2025 年 12 月 1 日（星期一）至 12 月 5 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 autobio@autobio.com.cn 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 郑州安图生物工程股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 8 日下午 15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 证券代码：603658 证券简称：安图生物 公告编号：2025-079 郑州安图生物工程股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 ...

Group 1 - Baidu's Biotech Company, Bai'ao Saitou, is set to launch its IPO on the Sci-Tech Innovation Board, aiming to raise 1.185 billion yuan for early drug development services, antibody drug research, and working capital [1] - Changchun High-tech's subsidiary received approval for its clinical trial application for GenSci142 capsules, marking the first approval under the new 30-day review channel for innovative drugs [2] - Antu Bio announced it received 18 medical device registration certificates, enhancing its product offerings and competitiveness in the market [3] Group 2 - Yidu Tech reported a revenue of 358 million yuan for the six months ending September 30, 2025, reflecting an 8.7% year-on-year growth, with a narrowed loss of 15.76 million yuan [4] - Baiyunshan's subsidiary, Guanghua Pharmaceutical, will receive a total compensation of approximately 449 million yuan for land and fixed assets included in a land reserve program, which aligns with the company's long-term development goals [5]